SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.
J Clin OncolJul 27, 2026 (epub)
Solange Peters, Roy Herbst, Hidehito Horinouchi et al.
✦ AI-curated · Sources linked
In 30 seconds
The SKYSCRAPER-01 study evaluated tiragolumab combined with atezolizumab in 521 patients with untreated, locally advanced unresectable or metastatic PD-L1-high non-small cell lung cancer. This phase III randomized controlled trial found that median progression-free survival was 7.0 months for the combination therapy compared to 5.6 months for placebo plus atezolizumab, with a hazard ratio of 0.78 (P = .02).
Key findings
- Median progression-free survival was 7.0 months with tiragolumab plus atezolizumab versus 5.6 months with placebo plus atezolizumab.
- The hazard ratio for progression-free survival was 0.78 (95% CI, 0.63 to 0.97; P = .02).
- Median overall survival was 23.1 months for the combination therapy compared to 16.9 months for placebo plus atezolizumab.
- 41.2% of patients experienced grade 3-4 adverse events with tiragolumab plus atezolizumab.
Why it matters
The findings suggest that while tiragolumab plus atezolizumab may improve progression-free survival in PD-L1-high non-small cell lung cancer, the lack of significant overall survival benefit raises questions about its clinical utility in this population.